Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of the patients according to the CyCAR criteria at baseline status (CTC1) and VEGFR status

From: Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

  CTC 1 CTC 1 VEGFR
N (%) − N (%) + p N (%) − N (%) + p
Age (years)
 < 55 15 (62.5%) 9 (37.5%) 0.622 3 (33.3%) 6 (66.7%) 1.00
 ≥ 55 29 (54.7%) 24 (45.3%) 7 (29.2%) 17 (70.8%)
Gender
 Male 30 (58.2%) 21 (41.2%) 0.808 9 (40.9%) 13 (59.1%) 0.144
 Female 14 (53.9%) 12 (46.1%) 2 (16.7%) 10 (83.3%)
Primary tumor location
 Colon 25 (54.4%) 21 (45.6%) 0.641 5 (23.8%) 16 (76.2%) 0.164
 Rectum 19 (61.3%) 12 (38.7%) 6 (46.2%) 7 (53.8%)
Metastasis surgery
 No 32 (57.1%) 24 (42.9%) 1.00 8 (32%) 17 (68%) 0.625
 Yes 12 (57.1%) 9 (42.9%) 3 (33.3%) 6 (66.7%)
Primary tumor surgery
 No 21 (75%) 7 (25%) 0.019* 4 (57.1%) 3 (42.9%) 0.132
 Yes 23 (46.9%) 26 (53.1%) 7 (25.9%) 20 (74.1%)
Synchronous metastasis
 No 3 (25%) 9 (75%) 0.024* 2 (22.2%) 7 (77.8%) 0.686
 Yes 41 (63.1%) 24 (36.9%) 8 (33.3%) 16 (66.7%)
K-RAS
 Mutated 25 (69.4%) 11 (30.6%) 0.061 4 (36.4%) 7 (63.6%) 0.546
 Wild-type 18 (46.2%) 21 (53.8%) 7 (31.8%) 22 (68.2%)
Basal CEA
 Standard 6 (40%) 9 (60%) 0.153 2 (20%) 8 (80%) 0.339
 High 37 (61.7%) 23 (38.3%) 8 (34.8%) 15 (65.2%)
Basal Ca 19.9
 Standard 19 (46.3%) 22 (53.7%) 0.034* 7 (31.8%) 15 (68.2%) 0.627
 High 23 (71.9%) 9 (28.1%) 3 (30%) 7 (70%)
Progression
 Yes 28 (53.8%) 24 (46.2%) 0.485 7 (29.2%) 17 (70.8%) 0.634
 No 9 (64.3%) 5 (35.7%) 2 (40%) 3 (60%)
Survival
 Yes 18 (60%) 12 (40%) 1.00 3 (25%) 9 (75%) 0.683
 No 22 (61.1%) 14 (38.9) 5 (35.7%) 9 (64.3%)
RECIST 12 weeks
 Favorable 31 (53.4%) 27 (46.6%) 0.402 7 (25.9%) 20 (74.1%) 0.557
 Adverse 3 (75%) 1 (25%) 0 (0%) 1 (100%)
RECIST 24 weeks
 Favorable 19 (52.8%) 17 (47.2%) 0.376 4 (23.5%) 13 (76.5%) 0.468
 Adverse 5 (38.5%) 8 (61.5%)   3 (37.5%) 5 (62.5%)
CyCAR 12 weeks
 Favorable 29 (65.9%) 15 (34.1%) 0.087 4 (26.7%) 11 (73.3%) 1.00
 Adverse 7 (38.9%) 11 (61.1%) 3 (27.3%) 8 (72.7%)
CyCAR 24 weeks
 Favorable 30 (55.6%) 24 (44.4%) 0.537 7 (29.2%) 17 (70.8%) 0.574
 Adverse 8 (66.7%) 4 (33.3%) 2 (50%) 2 (50%)
  1. *: Statistically significant
  2. CyCAR: Cytologic Criteria Assessing Response; CTC: circulating tumor cell; VEGFR: vascular endothelial growth factor receptor; RECIST: Response Evaluation Criteria in Solid Tumors; p: p value